• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗原性癌症持久性细胞能在T细胞的直接攻击下存活。

Antigenic cancer persister cells survive direct T cell attack.

作者信息

Wang Michael X, Mauch Brandon E, Williams August F, Barazande-Pour Tania, Araujo Hoffmann Filipe, Harris Sophie H, Lathrop Cooper P, Turkal Claire E, Yung Bryan S, Paw Michelle H, Gervasio David A G, Tran Tiffany, Stuhlfire Anna E, Guo Theresa, Daniels Gregory A, Park Soo J, Gutkind J Silvio, Hangauer Matthew J

机构信息

Department of Dermatology, University of California San Diego.

Department of Pharmacology, University of California San Diego.

出版信息

bioRxiv. 2025 Mar 17:2025.03.14.643359. doi: 10.1101/2025.03.14.643359.

DOI:10.1101/2025.03.14.643359
PMID:40166148
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11956947/
Abstract

Drug-tolerant persister cancer cells were first reported fifteen years ago as a quiescent, reversible cell state which tolerates unattenuated cytotoxic drug stress. It remains unknown whether a similar phenomenon contributes to immune evasion. Here we report a persister state which survives weeks of direct cytotoxic T lymphocyte (CTL) attack. In contrast to previously known immune evasion mechanisms that avoid immune attack, antigenic persister cells robustly activate CTLs which deliver Granzyme B, secrete IFNγ, and induce tryptophan starvation resulting in apoptosis initiation. Instead of dying, persister cells paradoxically leverage apoptotic caspase activity to avoid inflammatory death. Furthermore, persister cells acquire mutations and epigenetic changes which enable outgrowth of CTL-resistant cells. Persister cell features are enriched in inflamed tumors which regressed during immunotherapy and in surgically resected human melanoma tissue under immune stress . These findings reveal a persister cell state which is a barrier to immune-mediated tumor clearance.

摘要

十五 年前首次报道了耐药物的持久性癌细胞,它是一种静止、可逆的细胞状态,能够耐受未减弱的细胞毒性药物应激。目前尚不清楚类似现象是否会导致免疫逃逸。在这里,我们报道了一种持久性状态,它能在数周的直接细胞毒性T淋巴细胞(CTL)攻击中存活下来。与先前已知的避免免疫攻击的免疫逃逸机制不同,抗原性持久性细胞强烈激活CTL,CTL释放颗粒酶B、分泌IFNγ,并诱导色氨酸饥饿,从而引发细胞凋亡。持久性细胞非但没有死亡,反而反常地利用凋亡半胱天冬酶的活性来避免炎症性死亡。此外,持久性细胞会发生突变和表观遗传变化,从而使抗CTL细胞得以生长。持久性细胞特征在免疫治疗期间消退的炎症性肿瘤以及免疫应激下手术切除的人类黑色素瘤组织中富集。这些发现揭示了一种持久性细胞状态,它是免疫介导的肿瘤清除的障碍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/965cf22c539c/nihpp-2025.03.14.643359v1-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/c6ecbd970029/nihpp-2025.03.14.643359v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/dd37b0a518f7/nihpp-2025.03.14.643359v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/bc048cdfb7c2/nihpp-2025.03.14.643359v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/b930a35af42b/nihpp-2025.03.14.643359v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/8c7e212eb389/nihpp-2025.03.14.643359v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/965cf22c539c/nihpp-2025.03.14.643359v1-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/c6ecbd970029/nihpp-2025.03.14.643359v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/dd37b0a518f7/nihpp-2025.03.14.643359v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/bc048cdfb7c2/nihpp-2025.03.14.643359v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/b930a35af42b/nihpp-2025.03.14.643359v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/8c7e212eb389/nihpp-2025.03.14.643359v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be04/11956947/965cf22c539c/nihpp-2025.03.14.643359v1-f0007.jpg

相似文献

1
Antigenic cancer persister cells survive direct T cell attack.抗原性癌症持久性细胞能在T细胞的直接攻击下存活。
bioRxiv. 2025 Mar 17:2025.03.14.643359. doi: 10.1101/2025.03.14.643359.
2
Sublethal cytochrome c release generates drug-tolerant persister cells.亚致死细胞色素 c 释放产生药物耐受的休眠细胞。
Cell. 2022 Sep 1;185(18):3356-3374.e22. doi: 10.1016/j.cell.2022.07.025.
3
Glutathione Peroxidase 4 as a Therapeutic Target for Anti-Colorectal Cancer Drug-Tolerant Persister Cells.谷胱甘肽过氧化物酶4作为抗结直肠癌药物耐受持久性细胞的治疗靶点。
Front Oncol. 2022 Jun 3;12:913669. doi: 10.3389/fonc.2022.913669. eCollection 2022.
4
G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes.G6PD 作为代谢检查点,调节肿瘤特异性细胞毒性 T 淋巴细胞中颗粒酶 B 的表达。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003543.
5
Influence of interferon gamma on modulation of Fas expression by human colon carcinoma cells and their subsequent sensitivity to antigen-specific CD8+ cytotoxic T lymphocyte attack.干扰素γ对人结肠癌细胞Fas表达调节及其随后对抗原特异性CD8 + 细胞毒性T淋巴细胞攻击敏感性的影响。
Cancer Immunol Immunother. 2000 Jul;49(4-5):193-207. doi: 10.1007/s002620000105.
6
[Survival Mechanisms of Drug Tolerant Persister Cancer Cells against Targeted Anticancer Drugs].[耐药性持久性癌细胞对靶向抗癌药物的存活机制]
Gan To Kagaku Ryoho. 2023 Dec;50(12):1239-1245.
7
Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis.在细胞毒性T淋巴细胞(CTL)介导的靶细胞裂解过程中,凋亡途径被颗粒酶A和/或颗粒酶B选择性激活。
J Cell Biol. 2004 Nov 8;167(3):457-68. doi: 10.1083/jcb.200406115.
8
The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells.糖酵解抑制剂2-脱氧葡萄糖(2-DG)与索拉非尼联合使用可有效对抗耐索拉非尼的持久性癌细胞。
Onco Targets Ther. 2019 Jul 8;12:5359-5373. doi: 10.2147/OTT.S212465. eCollection 2019.
9
Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs.体外细胞毒性T淋巴细胞(CTL)诱导的颗粒酶B介导的细胞死亡:区分细胞死亡的必要条件及其一些特征。
Cell Death Differ. 2008 Mar;15(3):567-79. doi: 10.1038/sj.cdd.4402289. Epub 2007 Dec 7.
10
A Transient Metabolic State in Melanoma Persister Cells Mediated by Chemotherapeutic Treatments.化疗诱导的黑色素瘤持久性细胞中的短暂代谢状态
Front Mol Biosci. 2022 Jan 27;8:780192. doi: 10.3389/fmolb.2021.780192. eCollection 2021.

本文引用的文献

1
Cancer immune evasion, immunoediting and intratumour heterogeneity.癌症免疫逃逸、免疫编辑与肿瘤内异质性。
Nat Rev Immunol. 2025 May;25(5):353-369. doi: 10.1038/s41577-024-01111-8. Epub 2025 Jan 2.
2
A cell atlas foundation model for scalable search of similar human cells.一种用于可扩展搜索相似人类细胞的细胞图谱基础模型。
Nature. 2025 Feb;638(8052):1085-1094. doi: 10.1038/s41586-024-08411-y. Epub 2024 Nov 20.
3
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的10年最终结果
N Engl J Med. 2025 Jan 2;392(1):11-22. doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15.
4
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.癌症耐药性休眠细胞:从生物学问题到临床机遇。
Nat Rev Cancer. 2024 Oct;24(10):694-717. doi: 10.1038/s41568-024-00737-z. Epub 2024 Sep 2.
5
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.法尼基转移酶抑制克服了致癌基因依赖的非小细胞肺癌对靶向治疗的适应性耐药。
Nat Commun. 2024 Jun 27;15(1):5345. doi: 10.1038/s41467-024-49360-4.
6
Mitochondria and cell death.线粒体与细胞死亡。
Nat Cell Biol. 2024 Sep;26(9):1434-1446. doi: 10.1038/s41556-024-01429-4. Epub 2024 Jun 20.
7
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.联合 JAK 抑制和 PD-1 免疫疗法治疗非小细胞肺癌患者。
Science. 2024 Jun 21;384(6702):eadf1329. doi: 10.1126/science.adf1329.
8
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma.JAK 抑制增强霍奇金淋巴瘤患者的检查点阻断免疫治疗。
Science. 2024 Jun 21;384(6702):eade8520. doi: 10.1126/science.ade8520.
9
ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.ATF3可表征高级别浆液性卵巢癌中的侵袭性药物耐受持久性细胞。
Cell Death Dis. 2024 Apr 24;15(4):290. doi: 10.1038/s41419-024-06674-x.
10
Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.Xevinapant 联合帕博利珠单抗治疗晚期、预处理的结直肠癌和胰腺癌患者:CATRIPCA 试验的 Ib/II 期结果。
Clin Cancer Res. 2024 May 15;30(10):2111-2120. doi: 10.1158/1078-0432.CCR-23-2893.